¤â¨yºN¨ì¤£©úµw¶ô¡@³º¿©±w¨u¨£¥Ö½§Àù¡uÀq§J²Ó­MÀù¡v

2019-05-08 3009

Àq§J²Ó­MÀù¬O¤@ºØ¨u¨£ªº«I²¤©Ê¥Ö½§Àù¡A¸û¶Â¦â¯À½F§ó¬°´c©Ê¡B¯fµ{¶i®i§ó§Ö³t¡CÂù©MÂå°|ÁÂïú¦tÂå®v»¡©ú¡AÀq§J²Ó­MÀù¦b¥xÆW¤@¦~¤j¬ù·s¼W10-15¦ì®×¨Ò¡A¥L´¿¦¬ªv¤@¦W50·³ªº®×¨Ò¡A¥ý«e¦b¤â¨yºN¨ì¤£©úµw¶ô¡Aı±o¤£¹ï«l¦Ó¦Ü¥Ö½§¬ì´N¶E¡AÀˬd«á½T¶E¬OÀq§J²Ó­MÀù¡C

¡uÀq§J²Ó­MÀù¡v¬O¤@ºØ¨u¨£ªº«I²¤©Ê¥Ö½§Àù¡A¸û¶Â¦â¯À½F§ó¬°´c©Ê¡B¯fµ{¶i®i§ó§Ö³t¡CÂù©MÂå°|¦å²G¸~½F¬ìÁÂïú¦tÂå®v»¡©ú¡AÀq§J²Ó­MÀù¦b¥xÆW¤@¦~¤j¬ù·s¼W10-15¦ì®×¨Ò¡A¥L´¿¦¬ªv¤@¦W50·³ªº®×¨Ò¡A¥ý«e¦b¤â¨yºN¨ì¤£©úµw¶ô¡Aı±o¤£¹ï«l¦Ó¦Ü¥Ö½§¬ì´N¶E¡AÀˬd«á½T¶E¬OÀq§J²Ó­MÀù¡C¦]¬°µo²{ªº¦­¡A¶È¨Ï¥Î¤â³N¤Á°£¡A¥Ø«e±±¨î¨}¦n¡A¥u»Ý©w´Á¦^¶EÀˬd¡A¬GÁÂïú¦tÂå®v´£¿ô¯f¤Í¡AÁöµMÀq§J²Ó­MÀù¬°´c©Ê¸~½F¡A¦ý¥u­n¯à¤Î¦­µo²{¡AÁÙ¬O¯à¦³¸û¦nªº¯e¯f±±¨î¡A¬G¥Á²³­Yµo²{¨­Å馳¤£©úªºµi©Î¬O¬õµµ¦âµw¶ô¥X²{¡A½Ð¾¨¦­¦ÜÂå°|´N¶E¡C

Àq§J²Ó­MÀù¯fµ{µo®i§Ö¡@©ö»P¨ä¥L¸~½F²V²c

ÁÂïú¦tÂå®vªí¥Ü¡A®Ú¾Ú¬ã¨s¡A¥u¦³30-64%ªºÀq§J²Ó­MÀù±wªÌ¡]¤£½×´Á§O¬°¦ó¡^¯à°÷¦s¬¡5¦~¥H¤W¡F­Y¬°Âಾ©ÊªºÀq§J²Ó­MÀù¯f¤Í¡A¶W¹L5¦~¦s¬¡²v«h§C©ó20%¡]³Æµù1.2¡^¡C¨ä¦MÀI¦]¤l¥]§t¡G

1.ªø´Á·Ó®gµµ¥~½u¥B¥Ö½§¥ÕÞÕªº¥Á²³

2.´¿·P¬VHIV¡B±µ¨ü¾¹©x²¾´Ó¨üÅé¤Î¿©±wºC©Ê²O¤Ú²Ó­M¥Õ¦å¯f

3.¦~ÄÖ¤j©ó50·³¥H¤Wªº¥Á²³

¦]¬°Àq§J²Ó­MÀùªì´Á¯gª¬¤£©úÅã¡A¦ý¯fµ{¶i®i«Ü§Ö¡A¾É­P¦h¼Æ¯f¤Íµo²{Àù²Ó­M®É¡A¤wÂಾ¨ì²O¤Úµ²©Î¨ä¥L¾¹©x¡A¥B¿©±wÀq§J²Ó­MÀù«áªº´_µo²v¤Î­P¦º²v°ª¡A°£§½³¡´_µo¥~¡A¤]®e©öµo¥Í²O¤Ú¸¢Âಾ¬Æ¦Ü¬O¥þ¨­©ÊªºÂX´²Âಾ¦Ü¨xŦ¡B°©ÀY¡B¸£³¡¤Î¨ä¥L¾¹©x¡C¥t¥~¡A¦]¬°Àq§J²Ó­MÀù¦b¯f²z¤Á¤ù¤U¡A§e²{¶ê§ÎÂŦ⪺¤p²Ó­M¸~½F¡A»P¨ä¥L¼sªx³Q»{ª¾ªº¸~½F¡A¦p¡GÂಾ©Ê¤ºÅ¦¯«¸g¤º¤ÀªcÀù¸~½F¡BªÍÀù¡B²O¤ÚÀùªº¸~½F¬Û¦ü¡A¬G°ê¥~¬ã¨s«ü¥X¡A¶W¹L4¦¨Àq§J²Ó­MÀù¡A®e©ö»P¨ä¥L²O¤ÚÀù©Î¯«¸g¤º¤ÀªcÀù¯g²V²c¡]³Æµù3¡^¡I

¦]¦¹¡AÂå®v»Ý­n¶i¤@¨B´À¯f¤Í°µ§K¬Ì²Õ´¤Æ¾Ç¬V¦âÀËÅç(Immunohistochemistry, IHC)¡A§_«h¸ûÃø¶EÂ_¡A¦Ó¦­´ÁÀq§J²Ó­MÀùªºªvÀø¡A¥H¤â³N¤Á°£¬°¥D¡A­Y¸~½F¹L¤j©Î¯f¤Í¦~¨Æ¤w°ª¤£©y¤â³N¡A¥i¥H¨Ï¥Î©ñ®g½uªvÀø¤Î¤Æ¾ÇªvÀø±±¨î¯f±¡¡A¦ý¤]·|²£¥Í¸û¦hªº°Æ§@¥Î¡C¦ýÁÂïú¦tÂå®vªí¥Ü¡A¯f¤Íªº¯fÃÑ·PÁÙ¬O³ÌÃöÁ䪺¡C¥Á²³­Yµo²{¨­Å馳¤£©úµi©Îµw¶ô¥X²{¡AÀ³¤Î¦­´NÂå¡A¤~¯à¤Î¦­±±¨î¯f±¡¡C

Âå®v«Øij³z¹LA.E.I.O.U¡@¤f³Zªì¨B¿ëÃÑÁ{§É¯S¼x

ÁÂïú¦tÂå®v¤]§Æ±æ¥Ö½§¬ìÂå®v¡A­Y±µ¨ì¯f²z³ø§iÅã¥Ü¬°Âಾ©Ê¥Ö½§¯«¸g¤º¤ÀªcÀù¯g¡A°O±o½Ð¯f²z¬ìÂå®v°µCK20¬V¦â¡A­Y¬°¶§©Ê¡A«h¦³°ª¾÷²v¬°Àq§J²Ó­MÀù¡CÂå®v¤]¥i¥H³z¹L¥H¤UA.E.I.O.U¤f³Zªì¨B¿ëÃÑÁ{§É¯S¼x¡G

¡´Asymptomatic¡GµL©úÅã¯gª¬

¡´Expanding rapidly¡G¸~½F¨³³tÂX±i(≤3­Ó¤ë¤j´T¼Wªø)

¡´Immune suppression¡G´¿·P¬VHIV¡B±µ¨ü¾¹©x²¾´Ó¨üÅé¤Î¿©±wºC©Ê²O¤Ú²Ó­M¥Õ¦å¯f

¡´Older than 50 years age¡G¦~ÄÖ50·³¥H¤W

¡´UV­exposed area in a fair­skinned individual¡Gªø´Á·Ó®gµµ¥~½u¥B¥Ö½§¥ÕÞÕªº¥Á²³

°Ñ¦Ò¸ê®Æ¡G

1.Lemos B et al. Pathologic Nodal Evaluation Improved Prognostic Accuracy in Merkel Cell Carcinoma: Analysis of 5,823 Cases as the Basis of the First Consensus Staging System for this Cancer. Journal of the American Academy of Dermatology 2010;63:751¡V761.

2.NCCN Merkel Cell Carcinoma Guidelines Version I. 2017. Available from: www.nccn.org/professionals/physician_gls/PDF/mcc.pdf. Accessed August 2017.

3.Christopher K. Bichakjian, MD; Thomas Olencki, DO; Sumaira Z. Aasi, MD; Murad Alam, MD, MBA, MSCI; James S. Andersen, MD; Rachel Blitzblau, MD, PhD; Glen M. Bowen, MD; Carlo M. Contreras, MD; Gregory A. Daniels, MD, PhD; Roy Decker, MD, PhD;Jeffrey M. Farma, MD; Kris Fisher, MD; Brian Gastman, MD; Karthik Ghosh, MD; Roy C. Grekin, MD;Kenneth Grossman, MD, PhD; Alan L. Ho, MD, PhD; Karl D. Lewis, MD; Manisha Loss, MD;Daniel D. Lydiatt, DDS, MD; Jane Messina, MD; Kishwer S. Nehal, MD; Paul Nghiem, MD, PhD;Igor Puzanov, MD, MSCI; Chrysalyne D. Schmults, MD, MS;Ashok R. Shaha, MD; Valencia Thomas, MD; Yaohui G. Xu, MD, PhD; John A. Zic, MD;Karin G. Hoffmann, RN, CCM; and Anita M. Engh, PhDMerkel Cell Carcinoma, Version 1.2018

4.Author Patricia Tai, MB, BS, DABR, FRCR, FRCPC. Pathogenesis, clinical features, and diagnosis of Merkel cell (neuroendocrine) carcinoma

¥»¤å¸g °·±dÂåÀøºô ±ÂÅv¥Zµn¡A­ì¤åµoªí©ó¦¹
¡i°·±dÂåÀøºô¡þ°OªÌ´¿¥¿»¨³ø¾É¡j2019/05/06

ment,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', 'UA-35937129-1', 'auto'); ga('send', 'pageview');